RESEARCH ARTICLE

MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression

Lei Sun‡, Guangqing Bian‡, ZhaoJun Meng, Guangfu Dang, DeJing Shi, Shuyong Mi*

1 Department of Ophthalmology, The Fourth Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China, 2 Department of Ophthalmology, Shandong Provincial Qianfoshan Hospital, Jinan 250000, Shandong, China

‡ LS and GB are co-first authors on this work.
* widedoor@yeah.net

Abstract

MicroRNAs (miRNAs) are a group endogenous small non-coding RNAs that inhibit protein translation through binding to specific target mRNAs. Recent studies have demonstrated that miRNAs are implicated in the development of cancer. However, the role of miR-144 in uveal melanoma metastasis remains largely unknown. MiR-144 was downregulated in both uveal melanoma cells and tissues. Transfection of miR-144 mimic into uveal melanoma cells led to a decrease in cell growth and invasion. After identification of two putative miR-144 binding sites within the 3' UTR of the human c-Met mRNA, miR-144 was proved to inhibit the luciferase activity in MUM-2B cells with a luciferase reporter construct containing the binding sites. In addition, the expression of c-Met protein was inhibited by miR-144. Furthermore, c-Met-mediated cell proliferation and invasion were inhibited by restoration of miR-144 in uveal melanoma cells. In conclusion, miR-144 acts as a tumor suppressor in uveal melanoma, through inhibiting cell proliferation and migration. miR-144 might serve as a potential therapeutic target in uveal melanoma patients.

Introduction

Uveal melanoma, including choroidal and iris melanomas, is one of the most common types of primary intraocular malignancy, with an estimated annual incidence of ~5.1 cases per million [1, 2]. Uveal melanoma has a high rate of metastasis, mainly spreading hematogenously to liver [3, 4]. Early metastasis contributes to the high mortality rate of uveal melanoma[5, 6]. Although major advances have been made in the diagnosis and therapy of uveal melanoma, the 5-year relative survival rate has not improved from 1973 to 2008, especially in patients with metastatic disease[7]. Since the molecular mechanisms of its aggressiveness remain not elucidated, no therapy is effective for metastatic uveal melanoma patients[8, 9]. Therefore, understanding the
crucial signals that contribute to the invasive and metastatic potential of uveal melanoma might help to identify novel therapies for uveal melanoma patients.

MicroRNAs (miRNAs) are small (19–24nt), single stranded, noncoding RNAs, which can regulate gene expression posttranscriptionally[10–13]. Through binding to specific target mRNA, mature miRNAs can trigger mRNA degradation, stability or inhibition of translation [14–17]. Increasing evidences have shown that miRNAs play crucial roles in many biological processes, such as cell proliferation and apoptosis, glucose and lipids metabolism, signal transduction and responses[18–23]. In addition, miRNAs participate in human tumor genesis, which could add new insights into understanding the mechanisms of human malignancies[24, 25]. Aberrant miRNA expression is proved to associate with various human cancers, functioning as oncogenes or tumor suppressors [26–30].

In our study, miR-144 was down-regulated in uveal melanoma cells and tissues. Ectopic expression of miR-144 could inhibit uveal melanoma cell proliferation and invasion in vitro. Moreover, c-Met was identified as the potential targets of miR-144, and miR-144 might suppress tumor growth and invasion by repressing the expression of c-Met. Our findings suggest that miR-144 may function as a novel tumor suppressor gene in uveal melanoma and can be a potential therapy target for uveal melanoma.

Materials and Methods

Ethics statement

All patients were written informed consent in our study. Our study was approved by the Medical Ethics Committee of The Fourth Hospital of Harbin Medical University.

Samples collection and cell culture

Five tumor samples were collected from primary uveal melanomas patients and immediately frozen in liquid nitrogen. Tumor samples were stored at liquid nitrogen. Normal uveal samples were obtained from the Beijing Tongren Eye Bank (Beijing, China). The uveal melanoma cell lines (MUM-2B, C918, MUM-2C and OCM-1A) and the human melanocyte cell line (D78) were obtained from the Cell Bank of the Chinese Academy of Sciences (Beijing, People’s Republic of China). The OCM-1A and MUM-2C cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), which were supplemented with 10% fetal bovine serum (FBS) and MUM-2B, C918 in RPMI 1640 supplemented with 10% FBS.

qRT-PCR

Total RNA was isolated from frozen specimens (or the cells) using Trizol (Invitrogen). To measure the expression of miR-144, RNA (2μg) was used by quantitative RT-PCR (qRT-PCR) with the TaqMan microRNA assays reverse transcription kit according to manufacturer’s instructions (Applied Biosystems, Foster City, CA). U6 was used as internal control. Real-time PCR was performed with of cDNA (1μL) on Real-Time PCR System (Applied Biosystems, Foster City, CA) in duplicates. \(\Delta\Delta^{\text{CT}}\) represents the difference of CT values between internal control and miR-144. \(\Delta\text{CT}\) was used to present the difference of CT values between paired specimens. \(2^{\Delta\text{ACT}}\) means the exponential value of \(\Delta\text{CT}\), representing fold change in expression (S1 Table).

Cell proliferation

Cell proliferation was examined by the Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) assay, in accordance to manufacturer’s instructions. Absorbance was detected at 450
nm and measured by Quant Universal Microplate Spectrophotometer (BioTek Instruments, Inc.).

Oligonucleotide transfection
The miR-144 inhibitors, mimics and their controls were synthesised from GenePharma (Shanghai, China). Cells were transfected with them to a final oligonucleotide concentration at 20 nmol/L. Cell transfection processes were done by Lipofectamine 2000 (Invitrogen) following to the instructions.

Cell invasion assays
The transwell chambers were incubated to solidify with Matrigel (BD Biosciences, San Jose, CA, USA) at 37°C for 6 h. 4×10^5 cells were suspended in serum-free DMEM which added into the upper chamber after 24 h, and medium containing 10% FBS was put to the lower chamber. After 24 h, invasive cells on the lower chamber were stained and counted.

Western blot
Total protein was isolated from frozen tissues (or the cells) using Protein Extraction Kit (KeyGen, Nanjing, China). Proteins were separated using 10% SDS-PAGE and then transferred to PVDF membrane, which was incubated with the antibody for c-Met (Sigma, St. Louis, MO) or GAPDH (Cell Signaling Technology, Beverly, MA, USA). The membrane was washed and incubated with HRP-conjugated secondary antibody. Intensity of the bands was measured using the enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech) system and subsequently exposed.

Luciferase assay
MUM-2B cells were seeded in 24-well plates (1×10^5 cells/well) for 24 hours. For the reporter gene assay, cells were cotransfected with pGL3-c-Met-3'UTR (0.5 μg) or pGL3-c-Met-3'UTR mut plasmid, the phRL-SV40 control vector (0.05 ng, Promega, USA), and miR-144 mimic or scramble by Lipofectamine 2000 (Invitrogen, USA). The firefly and renilla luciferase activities were measured using the dual luciferase assay (Promega, USA) 24 hours after transfection.

Statistical analysis
Data was presented as mean ±SD. The differences between two groups were used Student’s t-test and the differences in more than two groups were used A one-way analysis of variance (ANOVA). All statistical analyses were performed using SPSS 16.0 (SPSS Inc., USA). P<0.05 was considered as statistically significant.

Result
MiR-144 was decreased in uveal melanoma cells and tissues
qRT–PCR analysis showed that the expression of miR-144 was decreased in uveal melanoma cell lines (MUM-2B, C918, MUM-2C and OCM-1A) compared with D78, human melanocyte cell line (Fig 1A). In addition, miR-144 was also decreased in human uveal melanoma tissues compared with normal uvea tissues (Fig 1B).
Overexpression of miR-144 inhibited proliferation and invasion of uveal melanoma cells

The expression of miR-144 was increased in MUM-2B cells transfected with miR-144 mimics, and decreased in cells transfected with miR-144 inhibitor (Fig 2A). The growth rate was reduced in MUM-2B cells transfected with miR-144 mimics compared with cells transfected with miR-144 inhibitors, scramble or control. (B) The CCK-8 proliferation assay showed that miR-144 mimics can inhibit the proliferation of the MUM-2B cells. Meanwhile, miR-144 inhibitor increased the proliferation of the MUM-2B cells. (C) Invasion analysis of MUM-2B cells after treatment with miR-144 mimics, inhibitors or scramble or control; the relative ratio of invasive cells per field is shown below, *p<0.05, **p<0.01, and ***p<0.001.

Fig 2. Overexpression of miR-144 inhibited proliferation and invasion of uveal melanoma cells (A) qRT–PCR analysis of miR-144 expression in MUM-2B cells which was transfected miR-144 mimics, inhibitors, scramble or control. (B) The CCK-8 proliferation assay showed that miR-144 mimics can inhibit the proliferation of the MUM-2B cells. Meanwhile, miR-144 inhibitor increased the proliferation of the MUM-2B cells. (C) Invasion analysis of MUM-2B cells after treatment with miR-144 mimics, inhibitors or scramble or control; the relative ratio of invasive cells per field is shown below, *p<0.05, **p<0.01, and ***p<0.001.

doi:10.1371/journal.pone.0124428.g002
with scramble mimics (Fig 2B). Meanwhile, miR-144 inhibitor promoted the MUM-2B cells proliferation (Fig 2B). The invasiveness of cells was decreased in cells transfected with miR-144 mimics compared with the scramble group and control group cells and increased in cells transfected with miR-144 inhibitor compared with the scramble group and control group (Fig 2C).

**c-Met is a critical downstream target of miR-144**

Analysis using available algorithms suggested that c-Met was a potential target gene of miR-144 (Fig 3A). Luciferase reporter gene assays showed that ectopic of miR-144 remarkably reduced luciferase activity in the c-Met wild-type reporter gene but not the mutant c-Met 3'UTR (Fig 3B). qRT-PCR analysis of c-Met expression in the MUM-2B cells which was transected miR-144 mimics, inhibitors, scramble or control. GAPDH was used as internal control. Western blot analysis has shown that miR-144 mimic inhibited the protein expression of c-Met in MUM-2B cells. GAPDH was also detected as a loading control. **p<0.001.

doi:10.1371/journal.pone.0124428.g003

**Downregulation of c-Met inhibits uveal melanoma cell proliferation and invasion**

Western blotting analysis showed that siRNA-c-Met inhibited the expression of c-Met (Fig 4A). Downregulation of c-Met decreased proliferation and invasion of uveal melanoma cell. When miR-144 inhibitor and si-c-Met were cotransfected into MUM-2B cells, miR-144 inhibitor enhanced the si-c-Met-induced inhibition of proliferation and invasion in uveal melanoma cells (Fig 4B and 4C).
Restoration of miR-144 inhibits c-Met-mediated uveal melanoma cell proliferation and invasion

Western blotting analysis demonstrated that pCDNA-c-Met enhanced the expression of c-Met (Fig 5A). Overexpression of c-Met promoted cell proliferation and invasion in uveal melanoma. In addition, when miR-144 mimic and pCDNA-c-Met was cotransfected into MUM-2B cells, miR-144 mimic repressed the pCDNA-c-Met-induced proliferation and invasion in uveal melanoma cells (Fig 5B and 5C).

Discussion

Emerging evidences have indicated that miRNAs have a crucial role in the pathogenesis of cancer through regulating genes involved in cell proliferation, migration, and invasion[15, 31–33]. Deregulation of miRNAs is common in cancers, where miRNAs might act as oncogene or putative tumor suppressor genes [34–36]. In the present study, miR-144 was downregulated in human uveal melanoma cells and tissues. Specifically, miR-144 inhibited cell proliferation and invasion. Target prediction and in vitro functional studies showed that c-Met was a direct target of miR-144. Importantly, miR-144 mimic rescued the c-Met-induced cell invasion and
proliferation. These findings suggest that miR-144 has an important role in inhibiting the development and progression of uveal melanoma.

There is increasing reports on the role of miR-144 in carcinogenesis[37]. MiR-144 was originally identified as an erythroid-specific miRNA, which was required for subsequent urvival and maturation of the erythroid lineage[38]. Downregulation of miR-144 was found in various cancers, such as hepatocellular carcinoma, lung cancer, and osteosarcoma[39–41]. Akiyoshi et al. proved that miR-144 expression was inversely correlated with gastric cancer [42]. Sureban et al. also showed that knockdown of doublecortin and CaM kinase-like-1 (DCAMKL-1) increased miR-144 expression, which in turn inhibited epithelial-mesenchymal transition (EMT) of pancreatic cancer[43]. However, there are also contradictory reports. Zhang et al. showed that miR-144 promoted proliferation, migration, and invasion of nasopharyngeal carcinoma through repressing phosphatase and tensin homolog (PTEN)[44]. Thus the function of miR-144 in carcinogenesis seems to be complicated and highly tissue-specific. However, the role of miR-144 in uveal melanoma remains unclear. In our study, the expression of miR-144 was downregulated in human uveal melanoma cells and tissues. Moreover, introduction of miR-144 can reduce uveal melanoma cell proliferation and invasion. These results suggest that miR-144 might act as a tumor suppressor gene whose down-regulation contributes to the progression and metastasis of uveal melanoma.

**Fig 5. Restoration of miR-144 inhibits c-Met-mediated uveal melanoma cell proliferation and invasion**

(A) The protein expression of c-Met was detected using western blotting analysis. (B) The cell growth in MUM-2B co-transfected with either miR-144 mimic and 2.0 μg pCDNA-c-Met or pCDNA empty vector using CCK-8 proliferation assay. (C) The cell invasive in MUM-2B cells co-transfected with either miR-144 mimic and 2.0 μg pCDNA-c-Met or pCDNA empty vector using invasion assay. *p<0.05, ** p<0.01, and ***p<0.001.

doi:10.1371/journal.pone.0124428.g005
MiRNAs control cellular functions by inhibiting the expression of genes; therefore, elucidation of their target gene is crucial. In the present study, for the first time, miR-144 was demonstrated to inhibit the proliferation and invasion of uveal melanoma cells by regulating the expression of c-Met. Activated MET oncoprotein, also known as c-MET, contribute to the tumorigenesis of a wide variety of cancers[45]. c-Met has a major influence on biological processes including cellular proliferation, migration and invasion[46]. Alterations of c-Met may play a role in tumorigenesis of many cancers such as gastric cancer, bladder cancer, and colorectal cancer[47–49]. Overexpression of c-Met is considered as a novel potential or even an independent predictor of poor prognosis for clinical patients[50]. Moreover, c-Met is overexpressed in 60% to 86% of solid tumors, and associated with tumor aggressiveness in uveal melanoma[51, 52]. Previous study showed that c-Met played a crucial role in the spreading of uveal melanoma in a murine model of selective liver metastasis[53]. C-Met activation was observed in uveal melanoma through indirect gene activation[54]. In our study, c-Met enhanced uveal melanoma cell proliferation and invasion; inhibition of c-Met reduced the uveal melanoma cell proliferation and invasion. Restoration of miR-144 inhibited c-Met-mediated uveal melanoma cell proliferation and invasion. These results demonstrate that miR-144 may act as a tumor suppressor in uveal melanoma by targeting c-Met.

In conclusion, the present study demonstrated that miR-144 was downregulated in uveal melanoma tissues and cell lines. Ectopic expression of miR-144 inhibited uveal melanoma cell proliferation and invasion. Further investigation revealed that c-Met was a potential target of miR-144. Therefore, miR-144 may serve as a potential therapeutic target in uveal melanoma patients.

Supporting Information
S1 Table. Primer sequence.

Author Contributions
Conceived and designed the experiments: LS GB ZM GD DS SM. Performed the experiments: LS GB ZM GD DS SM. Analyzed the data: LS SM. Contributed reagents/materials/analysis tools: LS SM. Wrote the paper: LS SM.

References
1. Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematol Oncol Clin North Am. 2012; 26(6):1169–84. doi: 10.1016/j.hoc.2012.08.004 PMID: 23116575
2. Shildkrot Y, Thomas F, Al-Hariri A, Fry CL, Haik BG, Wilson MW. Socioeconomic factors and diagnosis of uveal melanoma in the mid-southern United States. Current eye research. 2011; 36(9):824–30. doi: 10.3109/02713683.2011.593109 PMID: 21762015
3. Coupland SE, Lake SL, Zeschnigk M, Damato BE. Molecular pathology of uveal melanoma. Eye (Lond). 2013; 27(2):230–42. doi: 10.1038/eye.2012.255 PMID: 23222563
4. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9):1881–95. doi: 10.1016/j.ophtha.2011.01.040 PMID: 21704381
5. Sato T, Han F, Yamamoto A. The biology and management of uveal melanoma. Current oncology reports. 2008; 10(5):431–8. PMID: 18706273
6. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013; 119(20):3687–95. doi: 10.1002/cncr.28282 PMID: 23913718
7. Buder K, Gesierich A, Gelbrich G, Goebeler M. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer medicine. 2013; 2(5):674–86. doi:10.1002/cam4.133 PMID: 24403233

8. Yousef YA, Alkilany M. Characterization, treatment, and outcome of uveal melanoma in the first two years of life. Hematol Oncol Stem Cell Ther. 2014.

9. Rashid AB, Grossniklaus HE. Clinical, pathologic, and imaging features and biological markers of uveal melanoma. Methods Mol Biol. 2014; 1102:397–425. doi: 10.1007/978-1-62703-727-3_21 PMID: 24258990

10. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell proliferation. 2012; 45(1):32–8. doi:10.1111/j.1365-2184.2011.00798.x PMID: 22151897

11. Lee JE, Hong EJ, Nam HY, Kim JW, Jeon JP. Clinical, pathologic, and imaging features and biological markers of uveal melanoma. Methods Mol Biol. 2014; 1102:397–425. doi:10.1007/978-1-62703-727-3_21 PMID: 24258990

12. Li M, Yu M, Liu C, Zhu H, He X, Peng S, et al. miR-34c works downstream of p53 leading to dairy goat male germ line stem-cell (mGSCs) apoptosis. Cell proliferation. 2011; 44(1):59–66. doi:10.1111/j.1365-2184.2010.00717.x PMID: 21199010

13. Li J, Yu T, Jing J. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell proliferation. 2014; 47(2):152–60. doi:10.1111/cpr.12093 PMID: 24517182

14. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013; 4(5):665–76. PMID: 23714687

15. Yang WB, Chen PH, Hsu Ts, Fu TF, Su WC, Liaw H, et al. Sp1-mediated microRNA-182 expression regulates lung cancer progression. Oncotarget. 2014; 5(3):740–53. PMID: 24519909

16. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013; 4(5):665–76. PMID: 23714687

17. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012; 3(9):1011–25. PMID: 22948084

18. Marquitz AR, Mathur A, Shair KH, Raab-Traub N. Infection of Epstein-Barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(24):9593–8. doi: 10.1073/pnas.1202910109 PMID: 22647604

19. Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M, et al. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget. 2014; 5(17):7651–62. PMID: 25277195

20. Zhang C, Liu J, Wang X, Wu R, Lin M, Laddha SV, et al. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget. 2014; 5(9):9106–17. PMID: 25193859

21. Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013; 4(2):346–61. PMID: 23548312

22. Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 2014.

23. Stone N, Pangilinan F, Molloy AM, Shane B, Scott JM, Ueland PM, et al. Bioinformatic and genetic association analysis of microRNA target sites in one-carbon metabolism genes. PloS one. 2011; 6(7):e21851. doi:10.1371/journal.pone.0021851 PMID: 21765920

24. Naito Y, Yasuno K, Tagawa H, Sakamoto N, Oue N, Yashiro M, et al. MicroRNA-145 is a potential prognostic factor of scirrhou type gastric cancer. Oncology reports. 2014; 32(4):1720–6. doi: 10.3892/or.2014.3333 PMID: 25051317

25. Zhu ED, Li N, Li BS, Li W, Zhang WJ, Mao XH, et al. miR-30b, Down-Regulated in Gastric Cancer, Promotes Apoptosis and Suppresses Tumor Growth by Targeting Plasminogen Activator Inhibitor-1. PloS one. 2014; 9(8):e106049. doi: 10.1371/journal.pone.0106049 PMID: 25170877

26. Wu W, He X, Kong J, Ye B. Mir-373 affects human lung cancer cells' growth and its E-cadherin expression. Oncology research. 2012; 20(4):163–70. PMID: 23461063
27. Fei B, Wu H. MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro. Oncology research. 2012; 20(12):557–64. doi: 10.3727/096504013X13775486749254 PMID: 24139413

28. Zhang WH, Gui JH, Wang CZ, Chang Q, Xu SP, Cai CH, et al. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncology research. 2012; 20(4):139–47. PMID: 23461060

29. Yu L, Zhang J, Guo X, Li Z, Zhang P. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma. Cancer epidemiology. 2014; 38(4):408–13. doi: 10.1016/j.canep.2014.05.001 PMID: 24923856

30. Vrba L, Munoz-Rodriguez JL, Stampfer MR, Futscher BW. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PloS one. 2013; 8(5):e54398. doi: 10.1371/journal.pone.0054398 PMID: 23342147

31. Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, et al. Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget. 2014; 5(2):462–72. PMID: 24497324

32. Perilli L, Vicentini C, Agostini M, Pizzini S, Pizzi M, D’Angelo E, et al. Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget. 2014; 5(16):6611–9. PMID: 25115394

33. Chen X, He D, Dong XD, Dong F, Wang J, Wang L, et al. MicroRNA-124 is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Investigative ophthalmology & visual science. 2013; 54(3):2248–56.

34. Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. Plos one. 2012; 7(7):e40967. doi: 10.1371/journal.pone.0040967 PMID: 22848417

35. Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Investigative ophthalmology & visual science. 2013; 54(3):1193–9.

36. Chen X, Wang J, Shen H, Lu J, Li C, Hu DN, et al. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Investigative ophthalmology & visual science. 2011; 52(3):1193–9.

37. Zha W, Cao L, Shen Y, Huang M. Roles of Mir-144-ZFX pathway in growth regulation of non-small-cell lung cancer. PloS one. 2013; 8(9):e74175. doi: 10.1371/journal.pone.0074175 PMID: 24066116

38. Fu YF, Du TT, Dong M, Zhu KY, Jing CB, Zhang Y, et al. Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood. 2009; 113(6):1340–9. doi: 10.1182/blood-2008-08-174854 PMID: 18941117

39. Kallimutho M, Del Vecchio Blanco G, Di Cecilia S, Sileri P, Cretella M, Pallone F, et al. Differential expression of miR144* as a novel fecal-based diagnostic marker for colorectal cancer. Journal of gastroenterology. 2011; 46(12):1391–402. doi: 10.1007/s00535-011-0456-0 PMID: 21863218

40. Cao T, Li H, Hu Y, Ma D, Cai X. miR-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting E2F3. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35(11):10759–64. doi: 10.1007/s13277-014-2017-7 PMID: 25073510

41. Zhao M, Huang J, Gui K, Xiong M, Cai G, Xu J, et al. The downregulation of miR-144 is associated with the growth and invasion of osteosarcoma cells through the regulation of TAGLN expression. International journal of molecular medicine. 2014; 34(6):1565–72. doi: 10.3892/ijmm.2014.1963 PMID: 25318625

42. Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, et al. Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. British journal of cancer. 2012; 107(8):1345–53. doi: 10.1038/ijc.2012.326 PMID: 22955854

43. Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, et al. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology. 2011; 9:40. doi:10.1371/journal.pone.0040967 PMID: 22848417

44. Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Schwartz GK. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Molecular cancer therapeutics. 2013; 12(12):2817–26. doi: 10.1158/1535-7186.MCT-13-0499 PMID: 24140933

45. Wu X, Zhou J, Rogers AM, Janne PA, Benedettini E, Loda M, et al. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and
independently contribute to migration and metastatic potential. Melanoma Res. 2012; 22(2):123–32. doi: 10.1097/CMR.0b013e3283507fd PMID: 22343486

47. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014; 5 (7):1837–45. PMID: 24742823

48. Chiyomaru T, Seki N, Inoguchi S, Ishihara T, Mataki H, Matsushita R, et al. Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. International journal of oncology. 2014.

49. Lee J, Jain A, Kim P, Lee T, Kuller A, Princen F, et al. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PloS one. 2014; 9 (8):e103551. doi: 10.1371/journal.pone.0103551 PMID: 25090459

50. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2013; 26 (12):1632–41.

51. Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH. MET oncogene inhibition as a potential target of therapy for uveal melanomas. Investigative ophthalmology & visual science. 2010; 51 (7):3333–9.

52. Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PloS one. 2014; 9(2):e83957. doi: 10.1371/journal.pone.0083957 PMID: 24551032

53. Gardner FP, Serie DJ, Salomao DR, Wu KJ, Markovic SN, Pulido JS, et al. c-MET expression in primary and liver metastases in uveal melanoma. Melanoma Res. 2014; 24(6):617–20. doi: 10.1097/CMR.0000000000000118 PMID: 25211165

54. Economou MA, All-Ericsson C, Bykov V, Girmita L, Bartolazzi A, Larsson O, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Investigative ophthalmology & visual science. 2005; 46(12):4372–5.